Showing 3641-3650 of 4730 results for "".
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- DermTech Receives State of New York Laboratory Permithttps://practicaldermatology.com/news/dermtech-receives-state-of-new-york-laboratory-permit/2457864/DermTech, Inc., which specializes in non-invasive molecular dermatology, has received permitting from the State of New York, Department of Public Health. The addition of a New York permit to DermTech’s current accreditations, allows it to now provide laboratory services across the
- Burt's Bees Nature-Based Sensitive Skin Regimen Trumps Dermatologist-recommended Regimenhttps://practicaldermatology.com/news/burts-bees-nature-based-sensitive-skin-regimen-trumps-dermatologist-recommended-regimen/2457860/Burt's Bees nature-based sensitive line outperformed a dermatologist-recommended synthetic control regimen in a study of 120 people with clinically diagnosed sensitive skin from rosacea, atopic dermatitis/eczema, or cosmetic intolerance. The nat
- New From BrandMD: Advanced Eyelash Growth Serumhttps://practicaldermatology.com/news/new-from-brandmd-advanced-eyelash-growth-serum/2457870/BrandMD's latest product, Advanced Eyelash Growth Serum, is now available. Advanced Eyelash Growth Serum has proven effective within as a little as two weeks of use, the company says. The proprietary formulation features a peptide complex, rich in Biochanin A, to help promo
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Short Course Radiation Best Longer Courses in Older Skin Cancer Patientshttps://practicaldermatology.com/news/short-case-radiation-best-longer-courses-in-older-skin-cancer-patients/2457899/Shorter courses of radiation seem to be better than longer ones for older patients receiving treatment for basal and squamous cell skin cancers, a recent Penn State College of Medicine physician’s st
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Dr. Brandt Skincare Rolls Out Two New Productshttps://practicaldermatology.com/news/dr-brandt-skincare-rolls-out-two-new-products/2457909/Dr. Brandt skincare is introducing Hydro Biotic Recovery Sleeping Mask and Antioxidant Water Booster. The new sleeping mask is powered by Dr. Brandt Skincare's Biotic Balancing Complex, an oligosaccharide and yogurt powder that helps restore n
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (